DENVER - Monday, October 21st 2013 [ME NewsWire]
(BUSINESS
WIRE)-- MPEG LA today announced that Diagnovus, LLC has entered into a
license for certain patent rights through Librassay®, a new one-stop
patent licensing program in the field of molecular diagnostics offered
by patent licensing leader MPEG LA.
“We
are pleased to welcome Diagnovus as a Licensee to the Librassay®
program,” said Larry Horn, President and CEO of MPEG LA. “MPEG LA,
through Librassay, provides a solution to the market’s growing need for
one-stop non-exclusive access to patent rights for diagnostic tests that
lead to personalized medical solutions. Just as MPEG LA’s origination
of patent pools provided a market-based solution for accessing consumer
electronics, video and information technologies, MPEG LA’s Librassay
delivers a similar solution to the healthcare market with the potential
for profound cost savings and quality of life benefits.”
“Librassay®
is the answer to a growing market need for licenses under patents in
support of emerging gene panel tests,” stated James Stover, Ph.D., Vice
President of Business Development at Diagnovus. “When the patents are
held by many different entities, securing licenses with each of them can
be a challenge – especially for a small, fast moving company like
Diagnovus. We welcome the convenience of Librassay’s efficient,
cost-effective, one-stop licensing platform. By enabling us to access
patent rights in a single transaction, Librassay allowed Diagnovus to
quickly secure a license and add to our ENGAUGETM product line, saving
valuable resources for what we do best – delivering personalized
information and services to physicians treating patients suffering from
underserved, aggressive and lesser-known diseases.”
“We
welcome diagnostic developers and service providers, large and small,
to visit the Librassay® website and contact us directly to lock in
access to diagnostic patent rights held by a growing number of
world-class research institutions,” added Kristin Neuman, Librassay
Executive Director.
Launched
in September 2012
(http://www.mpegla.com/Lists/MPEG%20LA%20News%20List/Attachments/83/n-12-09-27.pdf),
Librassay® makes diagnostic patent rights from the world’s leading
research institutions available to everyone through a single license. It
also offers patent holders the opportunity for wider adoption of their
technologies, reasonable compensation for their research investments and
the incentive to invest more. The program currently includes some 400
patents owned by Johns Hopkins University; Ludwig Institute for Cancer
Research; Memorial Sloan-Kettering Cancer Center; National Institutes of
Health (NIH); Partners HealthCare; The Board of Trustees of the Leland
Stanford Junior University; The Trustees of the University of
Pennsylvania; University of California, San Francisco; and Wisconsin
Alumni Research Foundation (WARF)
To
access the on-line Librassay® store, or request a copy of the Librassay
Patent Portfolio License, please go to www.librassay.com.
MPEG LA, LLC
As
the pioneer of the modern day patent pool, MPEG LA is now the world’s
leading independent provider of patent licenses offering wide access to
important technologies. By assisting users with access to patent rights
for their technology choices, MPEG LA offers licensing solutions that
create opportunities for wide adoption and fuel innovation. MPEG LA’s
original license for digital video compression helped produce the most
widely employed standard in consumer electronics history. It has become
the template for addressing patent thickets. Today MPEG LA manages
licensing programs consisting of more than 8000 patents in 74 countries
with over 160 licensors and more than 5800 licensees. For more
information, please refer to http://www.mpegla.com.
Diagnovus, LLC
Founded
in 2011 and based in Nashville, Tenn., Diagnovus is a specialized
molecular diagnostic company focused on delivering personalized
information and services to physicians treating patients suffering from
underserved, aggressive and lesser-known diseases. Its mission is to
improve the health of patients and quality of treatment decisions
through innovative molecular diagnostics that better inform physicians,
patients and their families facing these difficult disease prospects.
Its core principles are defined by a commitment to bringing personalized
genomics that will assist physicians in achieving better outcomes for
their patients and contribute to a more efficient use of healthcare
resources. Learn more at www.diagnovus.com.
Contacts
MPEG LA, LLC
Tom O’Reilly, 303-200-1710
toreilly@mpegla.com
Permalink: http://me-newswire.net/news/8883/en
No comments:
Post a Comment